Inside USP: Traditional Chinese Medicines and Western Regulatory Paradigms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Traditional Chinese Medicines and Western Regulatory Paradigms
Traditional Chinese Medicine is widely used, but questions persist regarding its regulatory status.


Pharmaceutical Technology
Volume 33, Issue 7, pp. 64-66

Conclusion

The USP–ChP annual scientific meeting brought together several experts to discuss the expanding use of TCM and associated regulatory issues. Modern research is ongoing in China and Western research facilities regarding the mechanisms of TCM's pharmacological action. USP will continue to exercise its role in developing TCM singular botanical ingredients via the dietary supplements and active drug and excipient moieties model.

James C. Griffiths, PhD, is vice-president of food, dietary supplements, and excipient standards at the US Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852-1709,

References

1. USP (Boston: Wells and Lilly, 1820).

2. FDA, Food Additive Petition Expedited Review—Guidance for Industry and Center for Food Safety and Applied Nutrition Staff (Rockville, MD, 1999), http://www.cfsan.fda.gov/~dms/opa-expe.html accessed Jan. 26, 2009.

3. FDA, Guidance for Industry: Frequently Asked Questions about GRAS (Rockville, MD, 2004), http://www.cfsan.fda.gov/~dms/grasguid.html accessed Jan. 26, 2009.

4. FDA, Numerical Listing of GRAS Notices (Rockville, MD, 2008), http://www.cfsan.fda.gov/~rdb/opa-gras.html accessed Jan. 26, 2009.

5. PL 103-417, Dietary Supplement Health and Education Act, 1994, http://www.fda.gov/opacom/laws/DSHEA.html accessed Jan. 26, 2009.

6. L. Bhattacharyya et al., "The Value of USP Public Standards for Therapeutic Products," Pharm. Res., 21, 1725–1731 (2004).

7. R.L. Williams et al., "Official USP Reference Standards: Metrology Concepts, Overview, and Scientific Issues and Opportunities," J. Pharm. Biomed. Anal., 40, 3–15 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here